BIO:ON Insight #2 · Jun 9, 2026
Two companies showed data. One changed its name. Guess which stock jumped 60%.
Zenas files obexelimab with the FDA after a 56% cut in relapse risk, BPGbio brings a mitochondria-targeting glioblastoma drug to ASCO, and a biotech rebrands as an AI and space company. Where does a biotech's value really come from?
What I learned this week
From the headlines alone, all three companies looked like they were winning this week. Peel back one layer and one is holding a p-value, one a PET scan, and one a new company name. Next time a biotech story lands in your feed, ask "so what's the evidence?" That one question is what trains your eye for this industry. See you next issue. 🙏
Yaehyun Lee · Quoted from the Editor's Insight I wrote for this issue.
Stories in this issue
- FDA Approvals
Zenas files a BLA for obexelimab in IgG4-related disease
Zenas BioPharmaobexelimab
- Clinical Trials
BPGbio's BPM31510 glioblastoma Phase 2 at ASCO
BPGbio
- Market Trends
Rocket One's biotech-to-AI rebrand sends its stock soaring
Rocket One
AI summary
- 1Zenas BioPharma filed obexelimab for IgG4-related disease with the FDA after a Phase 3 cut relapse risk by 56%.
- 2BPGbio presented Phase 2 progress for BPM31510, a mitochondria-targeting glioblastoma drug, at ASCO 2026.
- 3Hoth Therapeutics' stock jumped after rebranding toward AI and space — a warning sign of theme-chasing without data.
Relevant rolesRegulatory affairsR&DInvestment & IR
Summary and tags generated by AI from the issue text.
References
- 1.
- 2.
- 3.
Related insights
Other issues covering the same companies, drugs or topics